Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and tolerability of one-hour infusions given once daily for 5 consecutive days in a 21-day treatment cycle; to define a recommended phase 2 dose; and to learn more about the clinical activity of SNS-032.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.

NCT00091585

Neoplasms

COMPLETED PHASE1

Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors

NCT00094159

Neoplasms

COMPLETED PHASE1

Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors

NCT00519662

Advanced Solid Tumors

COMPLETED PHASE1

Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

NCT00820560

Solid Tumors and Hematologic Malignancy

COMPLETED PHASE1

A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors

NCT03934359

Advanced Solid Tumors

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the body), preliminary evaluation of biomarkers to see how the levels of certain proteins change after administration of SNS-032; assessment of the effects of SNS-032 on QT interval.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SNS-032 Injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to provide written informed consent
* Advanced, progressing solid tumor that has no cure

* In Stage 1, any advanced solid malignancy
* In Stage 2, advanced breast cancer, melanoma, or non-small cell lung cancer (NSCLC)
* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2
* Recovered from radiation therapy that may have been given in the last 21 days
* Recovered from surgery

Exclusion Criteria

* Prior exposure to SNS-032 (previously known as BMS-387032)
* Pregnant or breastfeeding
* Women or male partners of women who are able to have children but are unwilling to use an approved, effective means of birth control
* Took part in another clinical trial during the last 21 days
* Abnormal lab values for serum potassium, hemoglobin, neutrophils, platelets, creatinine, AST, ALT, or total bilirubin
* Brain metastases, if patient is not neurologically stable or has needed corticosteroids or anticonvulsants at anytime within the 28 day period before enrollment.
* Other active malignancies
* Prior pelvic radiation therapy to ≥ 25% of bone marrow reserve
* Any other condition that would keep the patient from safely taking part in the clinical trial

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No